This website uses cookies in order to improve our services. If you proceed visiting this website you accept the usage of cookies. For more info please read our Data Privacy statement.

 

Pancreatic Cancer NGS Panels


General Cancer Testing | Brain & CNS Cancer | Breast & Ovarian Cancer | Colorectal & Prostate Cancer | Endocrine & Thyroid Cancer | Gastric Cancer | Hematologic Cancer | Kidney Cancer | Lung Cancer | Pancreatic Cancer | Skin Cancer & Melanoma | Solid Tumors | Less Common Cancers


Tobacco smoking, obesity, and diabetes are some of the main risk factors for pancreatic cancer. Whereas, it is estimated that 5 to 10% of pancreatic cancers have an inherited component (Klein et al. 2004).

The most common type of pancreatic cancer is the pancreatic adenocarcinoma. The two major precursors of pancreatic adenocarcinoma are pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms (Ryan et al. 2014). Some genes where frequently mutations are observed in patients with pancreatic ductal adenocarcinomas and/ or intraductal papillary mucinous neoplasms are the: ARID1A, ARID1B, ATM, BRCA2, CDKN2A, GNAS, KRAS, RNF43, SMARCA1, SMAD4, TGF-βR1, TGF-βR2 and p53 genes (Ryan et al. 2014). 

On this page different NGS panels are introduced that target genes that are associated or supposed to be associated with increased risk for development of pancreatic cancer.

For more information on the targeted genes please contact the NGS panel provider, general information on pancreatic cancer are found on this website.


Pancreatic Cancer

Hereditary Pancreas cancer

Targeted genes APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, FANCC, MEN1, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53, XRCC2

Source: Mendelics

Invitae Pancreatic Cancer Panel

The Invitae Pancreatic Cancer Panel analyzes genes that are associated with a hereditary predisposition for pancreatic cancer. These genes were selected based on the available evidence to date to provide Invitae’s broadest test for pancreatic cancer.
The primary panel includes 20 genes that are associated with with hereditary pancreatic cancer. In addition to the primary panel, clinicians can also choose to include three genes that have limited evidence of association with pancreatic cancer.
Source: Invitae

PANCNEXT

PancNext is a next generation sequencing (NGS) panel that simultaneously analyzes 13 genes associated with increased risk for pancreatic cancer.
Genes on this panel include APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53. Full gene sequencing is performed for 12 of the genes (excluding EPCAM). Gross deletion/duplication analysis is performed for all 13 genes. Specific-site analysis is available for individual gene mutations identified in a family.
Source: Ambry Genetics

Pancreatic Cancer

Multi Gene Panel (11 Genes)
Targeted genes: BRCA2 CDKN2A CHEK2 MLH1 MSH2 MSH6 PALB2 PMS1 PMS2 PTEN STK11
Source: Medical Genetics Center

PANCREATIC CANCER NEXTGEN SEQUENCING (NGS) PANEL

The Pancreatic Cancer NextGen Sequencing Panel analyzes 10 genes (APC, ATM, CDKN2A, MLH1, MSH2, MSH6, PALB2, PAMS2, STK11 and TP53 that have been associated with familial pancreatic cancers. The mode of inheritance appears to be autosomal dominant and may show anticipation (Bartsch et al. 2012).
Source: Prevention Genetics

Pancreatic Cancer NGS Panel

Targeted Genes: APC, ATM, BAP1, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53
Source: Fulgent Diagnostics

Pancreatic Cancer Panel

The family history is suggestive of a predisposition to pancreatic cancer. Although the BRCA2, PALB2, CDKN2A, STK11, ATM, and Lynch syndrome genes are thought to account for a significant proportion of such cases, there are several other genes that cause an increased risk of pancreatic cancer.
Tested genes: APC, ATM, BRCA1, BRCA2, CDK4, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53, VHL, XRCC2

Source: GeneDx

Pancreatic cancer panel, targeted

Tested genes APC, ATM, BMPR1A, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS1, PMS2, PRSS1, SMAD4, STK11

Source: Centogene

Pancreatic Cancer: Sequencing Panel

The American Cancer Society estimates 46,420 people (23,530 men and 22,890 women) will be diagnosed with pancreatic cancer in 2014. The lifetime risk of developing pancreatic cancer is about 1 in 78 (1.47%). Pancreatic tumors arise from either the exocrine cells or endocrine cells of the pancreas.
Targeted genes: (14) APC, ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, PRSS1, STK11, TP53, VHL
Source: Emory Genetics Laboratory

PancSeq

PancSeq is an ultrasequencing panel (NGS), which analyzes simultaneously 12 genes associated with susceptibility to different types of hereditary pancreatic cancer.
Most pancreatic cancers are sporadic. Different studies have found that between 5-10 % of cases of pancreatic cancer are familial, especially in families where there are several people affected. Multiple known genes are involved in susceptibility to pancreatic cancer. PancSeq panel provides the possibility of simultaneous and accurate study of 12 genes related to pancreatic hereditary cancer.

Source: ACgen


Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Griffin C, Cameron JL, Yeo CJ, Kern S, Hruban RH (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds |PubMed|

Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma |PubMed|


Pin It